Literature DB >> 26294726

Growth differentiation factor 15 (GDF15) promotes osteoclast differentiation and inhibits osteoblast differentiation and high serum GDF15 levels are associated with multiple myeloma bone disease.

Marita Westhrin1, Siv Helen Moen1, Toril Holien1, Anne Kærsgaard Mylin2, Lene Heickendorff3, Oddrun Elise Olsen1, Anders Sundan1, Ingemar Turesson4, Peter Gimsing2, Anders Waage1, Therese Standal5.   

Abstract

Entities:  

Keywords:  GDF15; multiple myeloma; osteoblast differentiation; osteoclast differentiation

Mesh：

Substances：

Year:  2015        PMID： 26294726      PMCID： PMC4666344          DOI： 10.3324/haematol.2015.124511

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

Review 1.  Advances in the understanding of myeloma bone disease and tumour growth.

Authors:  Shmuel Yaccoby
Journal:  Br J Haematol       Date:  2010-03-11       Impact factor: 6.998

2.  Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.

Authors:  Peter Gimsing; Kristina Carlson; Ingemar Turesson; Peter Fayers; Anders Waage; Annette Vangsted; Anne Mylin; Christian Gluud; Gunnar Juliusson; Henrik Gregersen; Henrik Hjorth-Hansen; Ingerid Nesthus; Inger Marie S Dahl; Jan Westin; Johan Lanng Nielsen; Lene Meldgaard Knudsen; Lucia Ahlberg; Martin Hjorth; Niels Abildgaard; Niels Frost Andersen; Olle Linder; Finn Wisløff
Journal:  Lancet Oncol       Date:  2010-10       Impact factor: 41.316

3.  Positive regulation of osteoclastic differentiation by growth differentiation factor 15 upregulated in osteocytic cells under hypoxia.

Authors:  Eiichi Hinoi; Hiroki Ochi; Takeshi Takarada; Eri Nakatani; Takashi Iezaki; Hiroko Nakajima; Hiroyuki Fujita; Yoshifumi Takahata; Shinya Hidano; Takashi Kobayashi; Shu Takeda; Yukio Yoneda
Journal:  J Bone Miner Res       Date:  2012-04       Impact factor: 6.741

4.  The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome.

Authors:  Asne R Bauskin; David A Brown; Simon Junankar; Krishan K Rasiah; Sarah Eggleton; Mark Hunter; Tao Liu; Dave Smith; Tamara Kuffner; Greg J Pankhurst; Heiko Johnen; Pamela J Russell; Wade Barret; Phillip D Stricker; John J Grygiel; James G Kench; Susan M Henshall; Robert L Sutherland; Samuel N Breit
Journal:  Cancer Res       Date:  2005-03-15       Impact factor: 12.701

5.  HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma.

Authors:  Therese Standal; Niels Abildgaard; Unn-Merete Fagerli; Berit Stordal; Oyvind Hjertner; Magne Borset; Anders Sundan
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

6.  Serum YKL-40: a new independent prognostic marker for skeletal complications in patients with multiple myeloma.

Authors:  Anne K Mylin; Niels Abildgaard; Julia S Johansen; Lene Heickendorff; Svend Kreiner; Anders Waage; Ingemar Turesson; Peter Gimsing
Journal:  Leuk Lymphoma       Date:  2015-02-11

7.  Growth/differentiation factor-15 inhibits differentiation into osteoclasts--a novel factor involved in control of osteoclast differentiation.

Authors:  Petr Vanhara; Eva Lincová; Alois Kozubík; Pierre Jurdic; Karel Soucek; Jan Smarda
Journal:  Differentiation       Date:  2009-08-19       Impact factor: 3.880

Review 8.  The multiple facets of the TGF-β family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1.

Authors:  Klaus Unsicker; Björn Spittau; Kerstin Krieglstein
Journal:  Cytokine Growth Factor Rev       Date:  2013-06-18       Impact factor: 7.638

9.  Bone marrow mesenchymal stem cells are abnormal in multiple myeloma.

Authors:  J Corre; K Mahtouk; M Attal; M Gadelorge; A Huynh; S Fleury-Cappellesso; C Danho; P Laharrague; B Klein; T Rème; P Bourin
Journal:  Leukemia       Date:  2007-03-08       Impact factor: 11.528

10.  Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin.

Authors:  O E Olsen; K F Wader; K Misund; T K Våtsveen; T B Rø; A K Mylin; I Turesson; B F Størdal; S H Moen; T Standal; A Waage; A Sundan; T Holien
Journal:  Blood Cancer J       Date:  2014-03-21       Impact factor: 11.037
View more
  13 in total

1.  Hypoxia promotes IL-32 expression in myeloma cells, and high expression is associated with poor survival and bone loss.

Authors:  Muhammad Zahoor; Marita Westhrin; Kristin Roseth Aass; Siv Helen Moen; Kristine Misund; Katarzyna Maria Psonka-Antonczyk; Mariaserena Giliberto; Glenn Buene; Anders Sundan; Anders Waage; Anne-Marit Sponaas; Therese Standal
Journal:  Blood Adv       Date:  2017-12-13

Review 2.  An Evidence-Based Approach to Myeloma Bone Disease.

Authors:  Nicholas Bingham; Antonia Reale; Andrew Spencer
Journal:  Curr Hematol Malig Rep       Date:  2017-04       Impact factor: 3.952

3.  Associations Between Plasma Growth and Differentiation Factor-15 with Aging Phenotypes in Muscle, Adipose Tissue, and Bone.

Authors:  Seung Hun Lee; Jee Yang Lee; Kyeong-Hye Lim; Young-Sun Lee; Jung-Min Koh
Journal:  Calcif Tissue Int       Date:  2021-09-09       Impact factor: 4.333

4.  FGFR2 accommodates osteogenic cell fate determination in human mesenchymal stem cells.

Authors:  Ying Zhang; Ling Ling; Arya Ajay D/O Ajayakumar; Yating Michelle Eio; Andre J van Wijnen; Victor Nurcombe; Simon M Cool
Journal:  Gene       Date:  2022-01-29       Impact factor: 3.913

5.  Plasma Growth and Differentiation Factor 15 Predict Longitudinal Changes in Bone Parameters in Women, but Not in Men.

Authors:  Yusuke Osawa; Toshiko Tanaka; Richard D Semba; Giovanna Fantoni; Ruin Moaddel; Julián Candia; Eleanor M Simonsick; Stefania Bandinelli; Luigi Ferrucci
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2022-10-06       Impact factor: 6.591

6.  GDF15 contributes to radioresistance and cancer stemness of head and neck cancer by regulating cellular reactive oxygen species via a SMAD-associated signaling pathway.

Authors:  Yan-Liang Li; Joseph T Chang; Li-Yu Lee; Kang-Hsing Fan; Ya-Ching Lu; Yi-Chen Li; Chang-Hsu Chiang; Guo-Rung You; Hsin-Ying Chen; Ann-Joy Cheng
Journal:  Oncotarget       Date:  2017-01-03

Review 7.  Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint.

Authors:  Jörg Wischhusen; Ignacio Melero; Wolf Herman Fridman
Journal:  Front Immunol       Date:  2020-05-19       Impact factor: 7.561

Review 8.  New Biomarkers of Ferric Management in Multiple Myeloma and Kidney Disease-Associated Anemia.

Authors:  Małgorzata Banaszkiewicz; Jolanta Małyszko; David H Vesole; Karolina Woziwodzka; Artur Jurczyszyn; Marcin Żórawski; Marcin Krzanowski; Jacek Małyszko; Krzysztof Batko; Marek Kuźniewski; Katarzyna Krzanowska
Journal:  J Clin Med       Date:  2019-11-01       Impact factor: 4.241

9.  Titanium Nanoparticles Enhance Production and Suppress Stabilin-1-Mediated Clearance of GDF-15 in Human Primary Macrophages.

Authors:  Lina S Silva-Bermudez; Tatyana N Sevastyanova; Christina Schmuttermaier; Carolina De La Torre; Leonie Schumacher; Harald Klüter; Julia Kzhyshkowska
Journal:  Front Immunol       Date:  2021-12-15       Impact factor: 7.561

10.  Serum protein fingerprinting by PEA immunoassay coupled with a pattern-recognition algorithms distinguishes MGUS and multiple myeloma.

Authors:  Petra Schneiderova; Tomas Pika; Petr Gajdos; Regina Fillerova; Pavel Kromer; Milos Kudelka; Jiri Minarik; Tomas Papajik; Vlastimil Scudla; Eva Kriegova
Journal:  Oncotarget       Date:  2016-08-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.